DanHong injection dose-dependently varies XXXX metabolites and metabolic pathways in the treatment of @entity35 with @entity2806 .

@entity1522 @entity8959 @entity2806 @entity2500 @entity3793 @entity51 @entity1188 @entity367 @entity563 @entity35 @entity1889 @entity3689 @entity2574
AIM: To determine how the relative @entity3689 contents and metabolic pathways regulate the pharmacological phenotypes in @entity35 with @entity2806 after treatment with varying doses of DanHong injection (DHI). METHODS: Adult male @entity35 underwent @entity2500 ( @entity2500 ), and were injected with DHI (DH-1: 1 mL/kg; DH-2: 2.5 mL/kg; DH-3: 5 mL/kg, and DH-4: 10 mL/kg, iv) daily for 3 d. The @entity51 score, body weights and @entity1188 volume were assessed. Serum levels of 20 free @entity1522 were determined using HPLC, and the values were transformed through the quantitative analysis of the @entity1522 in the serum metabolic spectrum. Multivariate statistical analysis methods (PCA and PLS-DA) and web-based metabolomics tools (MetPa and MetaboAnalyst) were used to analyze the biological data sets for the @entity1522 . RESULTS: Administration of DHI dose-dependently decreased cerebral @entity1188 volume, and ameliorated @entity51 . A total of 5, 6, 7 and 7 non-overlapping metabolites were identified in the DH-1, DH-2, DH-3, and DH-4 groups, respectively. Eight metabolites were shared between the DHI groups and the vehicle group. In addition, the serum levels of @entity367 , @entity2574 and @entity563 increased with increasing DHI dose. A total of 3, 2, 2 and 5 non-overlapping metabolic pathways were identified in the DH-1, DH-2, DH-3 and DH-4 groups, respectively, and @entity8959 , @entity563 , @entity1889 and @entity3793 metabolism were identified as overlapping pathways among the 4 dose groups. CONCLUSION: Overlapping and non-overlapping @entity3689 metabolites and metabolic pathways are associated with the dose-dependent neuroprotective effect of DHI.
